Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 9, 1998, Pages 887-892

  Laine, L ^a   Suchower, L ^b   Frantz, J ^b   Connors, A ^b   Neil, G ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Astra Merck Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUODENUM ULCER; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; DUODENAL ULCER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PENICILLINS;

EID: 0031689132     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00378.x     Document Type: Article

References (17)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. J Am Med Assoc 1994; 272: 65-9.
2. European Helicobacter pylori study group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997; 41: 8-13.
3. The Report on the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 1997; 113: S4-8.
4. Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993; 88: 1860-4.
5. Breuer T, Sudhop T, Malaty HM, Goodman K, Graham DY, Balfertheiner P. Do physicians from different countries treat H. pylori positive ulcer disease differently; a comparison between America and Germany. Gut 1996; 39(Suppl. 31): A189(Abstract).
6. Megraud F. Resistance of Helicobacter pylori to antibiotics. Aliment Pharmacol Ther 1997; 11(Suppl. 1): 43-53.
7. O'Morain C, Dettmer A, Rambow A, von Fritsch E, Fraser AG. Double-blind, multicenter, placebo-controlled evaluation of clarithromycin and omeprazole for Helicobacter pylori-associated duodenal ulcer. Helicobacter 1996; 1: 130-7.
8. Megraud F, Pichavant R, Palegry D, French PC, Roberts PM, Williamson R. Ranitidine bismuth citrate (RBC) co-prescribed with clarithromycin is more effective in the eradication of Helicobacter pylori than omeprazole with clarithromycin. Gut 1997; 41(Suppl. 1): A92(Abstract).
9. Tompkins DS, Perkin J, Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997; 2: 185-7.
10. Wurzer H, Rodrigo L, Stamler D, et al. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. Aliment Pharmacol Ther 1997; 11: 943-52.
11. Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol Rev 1997; 10: 720-41.
12. Osato MS, Flamm RK, Utrup LJ. Helicobacter pylori susceptibility testing: comparison of E-test and agar dilution methods, Gastroenterology 1998; 114: A250(Abstract).
13. Weissfeld AS, Simmons DE, Vance PH, Trevino E, Kidd S, Greski-Rose P. In vitro susceptibility of pre-treatment isolates of Helicobacter pylori from two multicenter United States clinical trials. Gastroenterology 1996; 110: A295(Abstract).
14. Weissfeld A, Haber M, Rose P, Kidd S, Siepman N. Geographical distribution in the United States of primary resistance to clarithromycin and metronidazole in patients infected wtih Helicobacter pylori. Gastroenterology 1997; 112: A328( Abstract).
15. Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996; 10: 251-6.
16. Yousfi MM, El-Zimaity HMT, Genta RM, Graham DY. One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10: 617-21.
17. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S ribosomal RNA are associated wtih clarithromycin resistance of Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-80.